What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

Find latest AML videos · 300+ videos

What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

By Rush University Medical Center FEATURING Ehab Atallah

308 views

May 29, 2024

Comments 0

ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

1.1K views

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

1.1K views

ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlig…

2024 ASH Annual Meeting Insights Hub

J. Zeidner

402 views

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

2024 ASH Annual Meeting Insights Hub

J. Watts

329 views

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

4.6K views

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

2024 ASH Annual Meeting Insights Hub

H. Fernandez

242 views

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

686 views

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

809 views

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

361 views

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

573 views

Cellular Therapies for Myeloid Malignancies

Moffitt Cancer Center

D. Sallman

134 views

Advancements in AML Management in 2024

Louisville Hematology Highlights

C. Lachowiez

174 views

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

588 views

Steroid-Refractory GVHD Updates

Roswell Park Comprehensive Cancer Center

S. Holtan

177 views

New

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

OncoPharm

J. Bossaer

16 views

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

525 views

ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax…

2024 ASH Annual Meeting Insights Hub

M. Amaya

123 views

New

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Insights from 2025 Tandem Annual Meeting

M. Al Malki

118 views

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

961 views

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

2.2K views

Login

Login

Join VuMedi

What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies

Related Videos

2025 Breast Cancer Highlights from International Medical Meetings: 5…

ASH 2024 Summary: Highlights in AML, MDS, and ALL

Debates in AML: 7+3 Is No Longer the Standard of Care

ASH 2024 Summary: Menin Inhibitors in AML - FDA Approval and Highlig…

ASH 2024 Insights: Venetoclax + Aza for 1L Younger AML Pts Independe…

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

ASH 2024 Summary: Transplant Options and Outcomes for TP53 Myeloid D…

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Myeloid Malignancies: Hot Topics in 2024

ESMO 2024 Summary: Highlights in Heme Malignancies

Cellular Therapies for Myeloid Malignancies

Advancements in AML Management in 2024

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

Steroid-Refractory GVHD Updates

Revumenib for KMT2A+ R/R Acute Leukemias - Drug Overview and Clinica…

Where I Use Azacitidine and Venetoclax in AML: Present and Future

ASH 2024 Insights: Clinical Study of Oral Azacitidine and Venetoclax…

Tandem 2025 Insights: PTCy-Based GVHD Prophylaxis After Mismatched U…

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

AML and MDS Highlights & Key Takeaways